144 related articles for article (PubMed ID: 31654227)
1. Simultaneous endocrine expression and loss of melanoma markers in malignant melanoma metastases, a retrospective analysis.
Steppert C; Krugmann J; Sterlacci W
Pathol Oncol Res; 2020 Jul; 26(3):1777-1779. PubMed ID: 31654227
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.
Wu Y; Lai Y; Zhang M; Li Z
Diagn Pathol; 2021 Aug; 16(1):78. PubMed ID: 34454530
[TBL] [Abstract][Full Text] [Related]
3. Loss of Conventional Melanocytic Markers in Malignant Melanoma and Lymph Node Metastasis; an Uncommon but Dangerous Pitfall.
Chang O; Argenyi Z
Am J Dermatopathol; 2017 Oct; 39(10):760-763. PubMed ID: 27759690
[TBL] [Abstract][Full Text] [Related]
4. Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases.
Romano RC; Carter JM; Folpe AL
Mod Pathol; 2015 Aug; 28(8):1033-42. PubMed ID: 26022451
[TBL] [Abstract][Full Text] [Related]
5. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.
Ben-Izhak O; Stark P; Levy R; Bergman R; Lichtig C
Am J Dermatopathol; 1994 Jun; 16(3):241-6. PubMed ID: 7524376
[TBL] [Abstract][Full Text] [Related]
6. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique.
Plaza JA; Suster D; Perez-Montiel D
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):421-5. PubMed ID: 18091385
[TBL] [Abstract][Full Text] [Related]
7. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases.
Eyden B; Pandit D; Banerjee SS
Histopathology; 2005 Oct; 47(4):402-9. PubMed ID: 16178895
[TBL] [Abstract][Full Text] [Related]
8. Metastatic malignant melanoma with neuroendocrine differentiation: a case report and review of the literature.
Juhlin CC; Zedenius J; Haglund F
J Med Case Rep; 2020 Mar; 14(1):44. PubMed ID: 32234068
[TBL] [Abstract][Full Text] [Related]
9. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
10. Epidermotropically metastatic malignant melanoma. Differentiating malignant melanoma metastatic to the epidermis from malignant melanoma primary in the epidermis.
Kornberg R; Harris M; Ackerman AB
Arch Dermatol; 1978 Jan; 114(1):67-9. PubMed ID: 619785
[TBL] [Abstract][Full Text] [Related]
11. Can Melan-A replace S-100 and HMB-45 in the evaluation of sentinel lymph nodes from patients with malignant melanoma?
Kucher C; Zhang PJ; Acs G; Roberts S; Xu X
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):324-7. PubMed ID: 16932024
[TBL] [Abstract][Full Text] [Related]
12. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision.
Abrahamsen HN; Hamilton-Dutoit SJ; Larsen J; Steiniche T
Cancer; 2004 Apr; 100(8):1683-91. PubMed ID: 15073857
[TBL] [Abstract][Full Text] [Related]
14. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions.
Trefzer U; Rietz N; Chen Y; Audring H; Herberth G; Siegel P; Reinke S; Königer P; Wu S; Ma J; Liu Y; Wang H; Sterry W; Guo Y
Arch Dermatol Res; 2000 Dec; 292(12):583-9. PubMed ID: 11214818
[TBL] [Abstract][Full Text] [Related]
15. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of melanin-related metabolites as markers of melanoma progression.
Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
[TBL] [Abstract][Full Text] [Related]
17. Potential predictive value of cofilin-1 for metastasis occurrence in a small cohort of Argentinian patients with mid-low Breslow thickness melanoma.
Ibañez IL; Grings FM; Bracalente C; Rinflerch AR; Volonteri V; Castro MAA; Klamt F; Durán H
Pathol Res Pract; 2019 Oct; 215(10):152582. PubMed ID: 31427165
[TBL] [Abstract][Full Text] [Related]
18. Primary anorectal malignant melanoma: an uncommon anorectal pathology.
Juanmartiñena Fernández JF; Fernández-Urien I; Córdoba A
Rev Esp Enferm Dig; 2016 Sep; 108(9):604-5. PubMed ID: 27056438
[TBL] [Abstract][Full Text] [Related]
19. Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.
Dorvault CC; Weilbaecher KN; Yee H; Fisher DE; Chiriboga LA; Xu Y; Chhieng DC
Cancer; 2001 Oct; 93(5):337-43. PubMed ID: 11668469
[TBL] [Abstract][Full Text] [Related]
20. S100, HMB-45, and Melan-A negative primary melanoma.
Shinohara MM; Deubner H; Argenyi ZB
Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
